These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Co-modification of IL-2-TNF alpha fusion gene and B7.1 gene to murine breast tumor cells leads to improved tumor rejection and vaccine effect.
    Author: Liu X, Zhang L, Zhang M, Ma Y, Xu X, Cai Y.
    Journal: Chin Med J (Engl); 2000 Feb; 113(2):167-71. PubMed ID: 11775545.
    Abstract:
    OBJECTIVE: To improve the vaccine potency of gene-modified tumor cells. METHODS: Using recombinant adenoviruses, we expressed the B7.1 gene in murine breast tumor cell line EMF6 and a subline previously transfected with retrovirus vector XdF harboring the IL-2-TNF alpha fusion gene. RESULTS: Immunization/challenge experiments demonstrated that IL-2-TNF alpha/B7.1 co-modified tumor cells possessed a lower tumorigenicity in vivo and an improved tumor-specific vaccine potency compared with single gene transfectant (P < 0.05). Three weeks after immunization with a variety of tumor cells, the mixed lymphocyte and tumor cells reaction assay (MLTB) and 51Cr-release assay were performed to test cellular immunity function. The results indicated that IL-2-TNF alpha and B7.1 together induced a more potent antitumor immune response than either molecule alone, 25% higher than IL-2-TNF alpha and 20% higher than B7.1, respectively. CONCLUSION: The IL-2-TNF alpha fusion gene and B7.1 gene act in concert to improve their antitumor effectiveness.
    [Abstract] [Full Text] [Related] [New Search]